miRNA-206在乳腺癌中的表达及与内分泌耐药相关性研究  

Expression of miRNA-206 in breast cancer and its correlation with endocrine resistance

作　　者：莫军扬[1] 张敏敏[1] 唐茜[1] 卢林捷 陈岩 韦业刚 覃舒婷[1] Mo Junyang;Zhang Minmin;Tang Qian;Lu Linjie;Chen Yan;Wei Yegang;Qin Shuting(General Surgery Department,Liuzhou People’s Hospital,Liuzhou 545006,China)

机构地区：[1]广西柳州市人民医院普外三科,柳州545006

出　　处：《广西医科大学学报》2021年第3期566-569,共4页Journal of Guangxi Medical University

基　　金：广西柳州市科学技术局资助项目(No.2019BJ10616);广西柳州市人民医院院内立项资助项目(No.Lry201317);广西区卫健委自筹课题资助项目(No.Z20190447)。

摘　　要：目的:分析乳腺癌组织中miR-206的表达水平,探讨其与临床特征、激素受体之间的关系。方法:收集2014年1月~12月入院的100例乳腺癌患者的癌组织标本,通过实时荧光定量聚合酶链反应(qPCR)检测miR-206的表达水平,分析其与乳腺癌临床特征,雌激素受体(ER)、孕激素受体(RP)的相关性。结果:腋窝淋巴结阳性患者癌组织中miR-206表达水平低于阴性者;miR-206在肿瘤直径≥2.0 cm癌组织中的表达水平低于直径<2.0 cm者;腋窝淋巴结移患者miR-206表达水平低于无转移患者,Ⅰ、Ⅱ期相比Ⅲ期患者,miR-206表达水平上调(P<0.05)。miR-206的表达水平与ER表达水平呈负相关关系、与患者无病生存率(DFS)之间呈正相关关系(均P<0.05)。结论:乳腺癌组织中miR-206的表达水平与临床特征密切相关,并可预测患者ER的表达情况。miR-206有望成为乳腺癌患者评估预后及内分泌治疗敏感度的一项新指标。Objective:to analyze the expression level of miR-206 in breast cancer tissues and to explore its relationship with clinical features and hormone receptors.Methods:Cancer tissues from 100 breast cancer patients admitted from Jan.to Dec.2014 were collected,and qPCR was used to detect the expression level of miR-206 and its correlation with clinical features of breast cancer,estrogen receptor(ER),progesterone receptor(PR)were analyzed.Results:The expression level of miR-206 in patients with positive axillary lymph nodes was lower than that in patients with negative axillary lymph nodes.The expression level of miR-206 in tumor tissues with d≥2.0 cm was lower than that in patients with d<2.0 cm.The expression level of miR-206 in patients with axillary lymph node metastasis was lower than that in patients without metastasis.The expression level of miR-206 was up-regulated in stageⅠ,Ⅱthan that in stageⅢ(P<0.05).The expression of miR-206 was negatively correlated with the expression of ER,and positively correlated with the disease-free survival rate(DFS).Conclusion:The expression level of miR-206 in breast cancer tissue is closely related to the clinical features,and can predict the expression of ER in patients with breast cancer.MiR-206 is expected to be a new index to evaluate the prognosis and endocrine therapy sensitivity of patients with breast cancer.

关 键 词：MiR-206 乳腺癌 临床特征 内分泌耐药 

分 类 号：R739.97[医药卫生—肿瘤]